The FDA staff review indicates that the company's Duchenne cell therapy data does not provide substantial evidence of effectiveness. This negative assessment from the FDA staff ahead of an advisory committee meeting is a significant setback for the therapy's approval prospects and will likely have a strong negative impact on the company's stock.
The FDA staff review, released ahead of an advisory committee meeting, states that the data for the company's Duchenne cell therapy does not provide substantial evidence of effectiveness. This is a critical development as the FDA staff's opinion heavily influences the advisory committee's recommendation and ultimately the FDA's approval decision. For Sarepta Therapeutics (SRPT), whose Duchenne gene therapy ELEVIDYS is the likely subject, this represents a major blow to its commercial prospects for this therapy. Short-term, SRPT's stock is expected to face significant downward pressure. Long-term, the company's pipeline and future revenue streams for Duchenne muscular dystrophy treatments could be severely impacted if this therapy fails to gain full approval or if its label is severely restricted.